El género como factor pronóstico de supervivencia postrasplante de células hematopoyéticas totipotenciales autólogas o alogénicas: experiencia de una sola institución

Background: Several variables influence the prognosis of patients after hematopoietic stem cell transplantation (HSCT), but there are discrepancies in the results of different studies that include gender as a prognosis factor. Objective: To determine the role of gender as a prognostic factor in overall survival (OS) post HSCT. Material and methods: Retrospective study of 285 patients undergoing HSCT between January 1993 and September 2012 in the Clinica Ruiz de Puebla. Results: In the period indicated, 155 allogeneic transplants were done, 40% female and 60% male, diagnosed with acute myelogenous leukemia (AML) in 25%, acute lymphoblastic leukemia (ALL) in 23%, chronic mielogenous leukemia (CML) in 19%. The OS, in women, was 38% at 131 months and 35% at 155 months, in men. In the same period, 130 autologous transplants were performed, 48% female and 52% male, diagnosed with multiple myeloma in 38%, ALL in 17%, AML in 15%. The OS was 58% at 214 months in women, and 65% at 229 months, in men. The OS was calculated according to the Kaplan Meier method and linear regression was performed analyzing OS with gender, age, body mass index and underlying diagnosis basis, obtaining R2 of 0.0335. T test was performed for gender and OS, without statistical significance. Conclusions: In this study, which included autologous and allogeneic transplants, regardless of age or diagnsosis, there was no statistically significant difference in terms of gender in the OS post HSCT.